Introduction to Severe Psoriatic

What is/are Severe Psoriatic?

Severe Psoriatic - Objectives: The patient of severe psoriatic arthritis (PsA) is mainly treated with oral methotrexate, ciclosporin, and anti-tumor necrosis factor-alpha inhibitors (TNFi). ^[1] To determine the effectiveness of golimumab (GLM) in improving joint, periarticular structures and cutaneous manifestations in patients with moderate to severe psoriatic arthritis (PsA) with cutaneous psoriasis in different real-life clinical settings and 48-month drug survival. ^[2] Two cadaveric fingers with severe psoriatic arthritis were analyzed. ^[3] The latest advances in molecular-targeted therapies using biologics or small-molecule inhibitors help to sufficiently treat even the most severe psoriatic symptoms and the extra cutaneous comorbidities of psoriatic arthritis. ^[4] Authors determined the effect of anti-interleukin-17 therapies on the body composition and serum lipid and inflammatory parameters among severe psoriatic patients. ^[5] Authors determined the effect of interleukin (IL)-17 inhibitor therapy on arterial intima-media thickness (IMT) among severe psoriatic patients. ^[6] According to FSFI score, prevalence of sexual dysfunctions was significantly higher in moderate-severe psoriatic patients compared to controls. ^[7] COVID-19: case report A 66-year-old man developed COVID-19 during immunosuppressive treatment with methotrexate for severe psoriatic arthritis. ^[8] This study investigates these issues comparing the sub-populations of mild and moderate-to-severe psoriatic patients, with special attention to the association between sleep and pruritus. ^[9] The Zn was significantly decreased in smoker mild and severe psoriatic patients as related to nonsmokers’ referents and patients. ^[10] 1, 2, 3, 4, 5, 6 We present a patient with severe psoriatic skin and joint disease who has been treated with multiple combinations of dual biologic therapy, including ustekinumab plus etanercept for 12 months, secukinumab plus etanercept for 6 months, and guselkumab plus etanercept for 15 months. ^[11] Combination therapy of biologic agents with conventional systemic drugs has been proposed to optimize psoriasis treatment outcomes in unresponsive or partial responsive severe psoriatic patients. ^[12] The patient showed multiple severe psoriatic crumbly nails (nail psoriasis severity index [NAPSI] score of 69) and started ustekinumab treatment at standard dosage of 45 mg fl. ^[13]

Among Severe Psoriatic

Authors determined the effect of anti-interleukin-17 therapies on the body composition and serum lipid and inflammatory parameters among severe psoriatic patients. ^[1] Authors determined the effect of interleukin (IL)-17 inhibitor therapy on arterial intima-media thickness (IMT) among severe psoriatic patients. ^[2]

severe psoriatic patient

Authors determined the effect of anti-interleukin-17 therapies on the body composition and serum lipid and inflammatory parameters among severe psoriatic patients. ^[1] Authors determined the effect of interleukin (IL)-17 inhibitor therapy on arterial intima-media thickness (IMT) among severe psoriatic patients. ^[2] According to FSFI score, prevalence of sexual dysfunctions was significantly higher in moderate-severe psoriatic patients compared to controls. ^[3] This study investigates these issues comparing the sub-populations of mild and moderate-to-severe psoriatic patients, with special attention to the association between sleep and pruritus. ^[4] The Zn was significantly decreased in smoker mild and severe psoriatic patients as related to nonsmokers’ referents and patients. ^[5] Combination therapy of biologic agents with conventional systemic drugs has been proposed to optimize psoriasis treatment outcomes in unresponsive or partial responsive severe psoriatic patients. ^[6]

severe psoriatic arthritis

Objectives: The patient of severe psoriatic arthritis (PsA) is mainly treated with oral methotrexate, ciclosporin, and anti-tumor necrosis factor-alpha inhibitors (TNFi). ^[1] To determine the effectiveness of golimumab (GLM) in improving joint, periarticular structures and cutaneous manifestations in patients with moderate to severe psoriatic arthritis (PsA) with cutaneous psoriasis in different real-life clinical settings and 48-month drug survival. ^[2] Two cadaveric fingers with severe psoriatic arthritis were analyzed. ^[3] COVID-19: case report A 66-year-old man developed COVID-19 during immunosuppressive treatment with methotrexate for severe psoriatic arthritis. ^[4]